6 completed, 2 terminated, 1 active not recruiting, 1 unknown. 11 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 6, Terminated 2, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Eflornithine: new trials by email Literature Review of Eflornithine trials Research Report on Eflornithine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Eflornithine, Lomustine - Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma | Phase 3 | Unknown | Orbus Therapeutics, Inc. | 343 | 2016-07-01 | 2022-01-21 |
| Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Eflornithine, Eflornithine Placebo, Sulindac 150 MG - Familial Adenomatous Polyposis | Phase 3 | Completed | Cancer Prevention Pharmaceuticals, Inc. | 171 | 2013-10-01 | 2021-06-08 |
| S0820, Adenoma and Second Primary Prevention Trial Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac - Colorectal Neoplasms | Phase 3 | Active not recruiting | SWOG Cancer Research Network | 354 | 2013-08-23 | 2026-10-23 |
| Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 Fexinidazole, Nifurtimox, Eflornithine - Human African Trypanosomiasis (HAT), Sleeping Sickness | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 394 | 2012-10-01 | 2018-02-20 |
| A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) Eflornithine plus Sulindac, Eflornithine plus Placebo, Sulindac plus Placebo - Familial Adenomatous Polyposis | Phase 3 | Withdrawn | Cancer Prevention Pharmaceuticals, Inc. | 2011-03-01 | 2015-04-24 | |
| Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda Eflornithine plus Nifurtimox combination therapy - Trypanosomiasis, African | Phase 2 / Phase 3 | Terminated | Epicentre | 31 | 2002-10-01 | 2007-06-21 |
| Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d, melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d, nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d - Trypanosomiasis, African | Phase 3 | Terminated | Epicentre | 435 | 2001-03-01 | 2006-05-26 |
| Eflornithine in Treating Patients With Bladder Cancer eflornithine - Bladder Cancer | Phase 3 | Completed | National Cancer Institute (NCI) | 450 | 1999-02-01 | 2013-12-18 |
| Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps placebo, eflornithine, sulindac - Precancerous Condition | Phase 3 | Completed | National Cancer Institute (NCI) | 375 | 1998-07-01 | 2015-01-22 |
| Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer eflornithine - Non-melanomatous Skin Cancer | Phase 3 | Completed | University of Wisconsin, Madison | 2019-12-13 | ||
| Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis Eflornithine, Nifurtimox - Trypanosomiasis, African | Phase 3 | Completed | Drugs for Neglected Diseases | 280 | 2016-09-29 |
Trypanosomiasis, African (4) · Adenomatous Polyposis Coli (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Basal Cell (1) · Colonic Polyps (1) · Colorectal Neoplasms (1) · Glioma (1) · Precancerous Conditions (1) · Trypanosomiasis (1) · Urinary Bladder Neoplasms (1)
Cancer Prevention Pharmaceuticals, Inc. (2) · Drugs for Neglected Diseases (2) · Epicentre (2) · National Cancer Institute (NCI) (2) · Orbus Therapeutics, Inc. (1) · SWOG Cancer Research Network (1) · University of Wisconsin, Madison (1)
United States (5) · Belgium (2) · Canada (2) · Democratic Republic of the Congo (2) · Germany (2) · Netherlands (2) · Republic of the Congo (2) · Uganda (2) · United Kingdom (2) · Central African Republic (1) · France (1) · Italy (1) · Spain (1)
Gerardo Priotto, MD, MPH (2) · Alfred M. Cohen, M.D. (1) · Carol Burke, M.D. (1) · Els Torreele, PhD (1) · Frank Meyskens (1) · Gerardo Priotto, MD MPH (1) · James Church, M.D. (1) · Jason A. Zell, D.O., MPH (1) · Mark Mayle (1) · Patrice Piola, MD MSc (1) · Paul P. Carbone, MD (1)
PMID 19559476, PMID 20538001, PMID 29113731, PMID 32905675, PMID 34261858, PMID 41325560
R01CA088078 (1), U01CA077158 (1), U10CA037429 (1)